New hope for tough colon cancer? drug targets rare gene flaw
NCT ID NCT07435584
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called everolimus in people with advanced colorectal cancer that has a specific genetic change (CDK12 deficiency) and has not responded to other treatments. The goal is to see if the drug can shrink tumors or slow the cancer's growth. About 38 adults will take everolimus pills, and researchers will monitor safety and how well it works.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a plasma beam stop colon polyps from coming back?
- A stitch in time: could a device make abdominal closure safer?
- Can we predict chemo brain before it happens?
- Your gut bacteria might reveal hidden cancer risk
- Can a smart digital program restore sleep for cancer survivors?
- Can a new infusion drug shrink Hard-to-Treat tumors?